Tecentriq + tiragolumab does not improve OS, updated phase III data finds

As USPSTF falters, the idea that “screening is always good” is gaining traction

With the pope’s lung cancer diagnosis jumpstarting conversations about lung cancer screening and the constant buzz surrounding multi-cancer detection tests, evidence-based evaluation of screening tests is more important than ever.

October 21, 2026

News Analysis

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening
“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”

Pope Leo XIV has been diagnosed with lung adenocarcinoma. According to missives from the Holy See, the pope underwent surgery to remove the lower lobe of his right lung Oct. 13.

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

Chronic exposure to cigarette smoke may reprogram different populations of lung stem cells, which maintain and repair lung tissue, in ways that make them vulnerable to specific cancer-causing gene alterations and ultimately helps determine the type of lung cancer that develops.

October 09, 2026

Vol.52 No.37

Clinical Roundup

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, FDA has approved two KRAS inhibitors to treat patients with specific KRAS mutations. While these drugs can work well initially, tumors almost always develop resistance to them.

October 02, 2026

Vol.52 No.36

Perspective

When did stage 3B lung cancer become “early stage”?

My recent column about Merck’s television commercial for perioperative Keytruda left me with a question I could not shake.

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial.

September 25, 2026

Vol.52 No.35

Tecentriq + tiragolumab does not improve OS, updated phase III data finds

YOU MAY BE INTERESTED IN

As USPSTF falters, the idea that “screening is always good” is gaining traction

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening
“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

When did stage 3B lung cancer become “early stage”?

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Renew today!

Subscriber content

Never miss an issue!

Login

Tecentriq + tiragolumab does not improve OS, updated phase III data finds

YOU MAY BE INTERESTED IN

As USPSTF falters, the idea that “screening is always good” is gaining traction

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

When did stage 3B lung cancer become “early stage”?

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Never miss an issue!

Login

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening
“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”